

PAN MERSEY AREA PRESCRIBING COMMITTEE MEETING

Minutes of the Meeting held on Wednesday 12th February 2014 in the Gallery, Huyton Civic Suite, Civic Way Off Poplar Bank, Huyton. L36 9GD

Chairperson's signature:



Date:

2.4.2014

Present:


Dr MG Semple (APC Chair)	Senior Lecturer in Child Health – Alder Hey Children's NHS Foundation Trust
Dr Michael Ejuoneatse	Clinical Lead for Medicines – St Helens CCG
Simon Gelder	Chief Pharmacist – St Helens & Knowsley Teaching Hospitals NHS Trust
John Davey	LPC Representative
Gillian Gow	Chief Pharmacist – Liverpool Heart and Chest FT
Dr Catherine Doyle	GP Clinical Lead Medicines Management- Warrington CCG
Paul Skipper	Assistant Director of Pharmacy – Royal Liverpool University Hospital Trust
Steve Simpson	Deputy Chief Pharmacist – Southport & Ormskirk NHS Trust
Dave Thornton	Principal Pharmacist, Clinical Services, Univ. Hosp. Aintree
Lucy Reid	Senior Pharmacist – Halton CCG
Dr Janice Eldridge	GP Medicines Management Lead – Southport & Formby CCG
Peter Johnstone	CCG Lead Medicines Management- Liverpool CCG.
Jenny Lunn	Medicines Management Lead – Warrington CCG
Dr Shamin Rose	GP Prescribing Lead & Board sponsor – Liverpool CCG
Dr Tom Kennedy	Consultant & MMG Chair - Royal Liverpool University Hospital
Isam Badhawi	Deputy Chief Pharmacist – Liverpool Women's Hospital NHS Foundation Trust
Sarah McParland (on behalf of Lorraine Prescott)	Senior Pharmacist - 5 Borough's Partnership NHS Foundation Trust
Dr Cecilia Jukka	Southport & Ormskirk NHS Trust and Chair of D & T
Dr Anna Ferguson	GP Clinical Lead, South Sefton CCG
Brendan Prescott	Medicines Management – South Sefton CCG & Southport & Formby CCG

In Attendance:

Anne Henshaw	Senior Pharmacist - CMCSU
Clare Moss	Senior Pharmacist - CMCSU
Dr Niall Furlong	Consultant Diabetologist – St Helens & Knowsley Teaching Hospitals NHS Trust (Attended for Diabetes guidelines agenda item only)
Donna Gillespie – Greene	Joint Deputy Head of Medicines Management - CMCSU
Graham Reader	Senior Pharmacist - CMCSU
Cassandra Edgar	Advanced Clinical Pharmacist Formulary & Management – St Helens & Knowsley Teaching Hospitals NHS Trust
Maureen Hendry	Medicines Management - Liverpool Community Health

1	<p>APC/14/10 – Welcome and Apologies for Absence The Chair welcomed the Committee members to the meeting.</p> <p>Apologies were received from the following members: Dr Aftab Hossain (Knowsley CCG), Nicola Baxter - West Lancs CCG, Erika Baker (CMCSU), Jenny Jones (Warrington Hospital), Alison Butt (LCH), Sid McNulty (Whiston Hosp), Neil Mercer (Univ Hosp Aintree), Claire Forde (Halton CCG), Catrin Barker (Alder Hey), Heather Tomlinson (Bridgewater), Margaret Geoghegan (St. Helens CCG).</p>	
2	<p>APC/14/11 – Declarations of Interest and Quoracy check A quoracy check informed that there were 5 Primary Care clinicians and 3 Secondary Care Consultants present at this meeting. This meeting was quorate.</p> <p>There were no declarations of interest at this meeting.</p> <p>The Chair confirmed that following the unanimous vote (in favour) at the last meeting, no objections were received from committee members and therefore P.J., from Liverpool CCG, would be taking up the position of APC Deputy Chair.</p>	
3	<p>APC/14/12 – Minutes of the previous meeting and matters arising. 14/12/1 – Minutes from the previous meeting The Chair asked the members for any inaccuracies in the draft minutes.</p> <p>It was clarified that triptorelin 22.5 mg (item: 14/04/05) on the minutes was correct, and that the paper from the previous meeting where it stated "11.25mg" was incorrect.</p> <p>Matters Arising: 14/12/2 – Prescribing overseas advice The members were updated with a summary of the changes to the Policy Statement requested at the previous meeting, including removing "routinely" from "the durations in excess of 3 months" in the first paragraph. A link to NHS Choices' website advising patients on leaving the UK and entering other countries with medicines has now been added. Also now states to follow NHSE advice if their policies are different and he pointed out that the references at the bottom have been changed. The statement was approved by the Committee.</p> <p>14/12/3 – Magnesium Glycerophosphate The members were updated with the amendments to the Magnesium Glycerophosphate entry in the formulary. A paragraph has been added to advise prescribers for patients who are using it for nutritional reasons that nutritional supplements are available for purchase over the counter. This was approved by the Committee.</p>	<p>Action: GR</p> <p>Action: GR</p>
4	<p>APC/14/13 – New Medicines 14/13/1 - APC report – New Medicines Subgroup meeting rescheduling 2014 The members were updated regarding the rescheduled meeting dates for the NMSG. The NMSG will meet on the 28th March and then not again until the 9th May 2014 to accommodate the change to NMSG meeting scheduling, which will facilitate the timely approval of NICE TA policy statement recommendations by both APC and CCGs. As a result of this change, the NMSG will meet 10 times in 2014 rather than the 11 meetings stated in the Terms of Reference (ToR), therefore it was felt necessary to obtain committee approval for this one-off deviation from the ToR. This was approved by the Committee.</p>	

	<p>14/13/2 - Grey statement summary The summary was presented of grey statements which have been produced by the NMSG for Alogliptin, Aripiprazole depot injection, Canagliflozin, Lubiprostone and Meningococcal Group B Vaccine and confirmed they have been uploaded to the APC website in accordance with the agreed process. Approved.</p> <p>14/13/3 – Horizon Scanning update The Horizon Scanning process for the financial year 2014/15 has been completed and an update was given. No objections.</p> <p>14/13/4 – Rifaximin update It was reported that there is now no expected date for the NICE Technology Appraisal (originally expected in Oct 2013) of Rifaximin and therefore the two CCGs that had not approved the Amber policy statement because they were awaiting the NICE TA may wish to review their position now that NICE publication is not expected imminently. It was proposed that the amber status is retained until further information is available from NICE. There was a discussion around changing to grey status. It was put to the vote and the majority decision was to maintain amber status for now. A request to obtain costing information was made. It was also suggested that we monitor the extent of its use. The Chair asked that this item be put on the Agenda in two months' time.</p>	<p>Action: AH</p> <p>Action: DGG</p>
5	<p>APC/14/14 – Formulary and Guidelines</p> <p>14/14/01 – Ferrous fumarate statement removal A request was made to give approval to remove the ferrous fumarate policy statement from the website following a change in price. Switching to ferrous fumarate is no longer recommended although it remains 1st choice oral iron treatment. This was approved by the members' unanimous vote.</p> <p>14/14/02 – Doxazosin m/r statement There was discussion about the recommendation to "switch" medication in paragraph two from m/r to standard release formulation. There were concerns that it was not for the APC to dictate policy but to give guidance. Additionally, members expressed concern that changing medication back and forth carries a risk and they have a duty to limit risk. It was proposed by the Chair to add the word "consider" to paragraph two. After further discussion, this statement was approved with the amendment as above.</p> <p>14/14/03 – Diabetes Guidelines update The Diabetes Guidelines were presented on behalf of the author and it was reported that the intention was they will now be put on the Pan Mersey website. It was confirmed that they are, in the main, NICE aligned. There followed a discussion about the blood pressure levels for diabetic nephropathy of a single target and it was confirmed this was in line with QOF targets It was noted on Page 11 of the guidelines do not follow recently updated APC recommendations and the author was requested to change with regard to aspirin in stroke prevention. The document 'antiplatelet therapy for the prevention of occlusive vascular events' will be forwarded to the authors. A note was made that PCT needs to be changed to CCG throughout. After minor amendments have been made then this will be approved by chair's action.</p> <p>14/14/04 – Rosuvastatin statement</p>	<p>Action: CE</p> <p>Action: CE</p> <p>Action: CE</p> <p>Action: NF/KH</p>

	<p>An update was presented to the committee which proposed that the RAG rating should change from Amber to Green, but otherwise prescribing recommendations regarding its limited place remain the same. This was statement approved unanimously.</p> <p>14/14/05 – Dexamethasone intravitreal implant – non-infectious uveitis statement</p> <p>The FGSG recommendations were presented to the committee. It was pointed out that the trial shows benefits but this is only for one dose and that there is uncertainty about frequency of dosing and duration of treatment beyond this. A member asked for data from providers on these aspects after 12 months' use if approved –but it was agreed that this is a matter for CCGs to decide if they wish providers to do this.</p> <p>This statement was approved</p> <p>14/14/06 – FGSG process</p> <p>The flow chart of the FGSG review process and associated forms were presented.</p> <p>These were approved.</p>	Action: GR
6	<p>APC/14/15 – Safety</p> <p>14/15/1 – Safety update</p> <p>The members were updated around the work undertaken by the Safety subgroup. After another month's feedback, a summary of the Interface forms will be produced. A review will be produced regarding drug recalls (following the discussion at January's meeting) after consultation with colleagues through the NHSE. A request was made that the Cheshire NHSE Area team are also consulted.</p> <p>Further updates on the safety work plan were provided as</p> <p></p> <p>20141102 safety subgroupupdate Feb. attached.</p>	Action: CM
7	<p>APC/14/16 – Shared Care</p> <p>14/16/1 – Shared Care update</p> <p>A verbal update was presented.</p> <p>SCA for Atypical Antipsychotics and DMARDs are out to consultation. Reviews of Lithium and Denosumab SCA have commenced.</p> <p>A new SCA for DMA for Gastroenterology and Neurology will be started.</p>	Action: CM
9	<p>APC/14/17 – Any Other Business</p> <p>Patient and Public Representation</p> <p>The members were informed that the Patient Public Representative Group have met twice this year. All of them expressed an interest in attending this meeting. However, they requested travelling expenses. The CMCSU will liaise with patient and public representatives and find out how many wish to attend. It was suggested that perhaps several lay members could attend but only one would speak on their behalf.</p> <p>A discussion took place about the representation of lay people at this committee. It was suggested that committee members present think about this and it will be discussed at the next meeting.</p>	<p>Action: DGG</p> <p>Action: EB</p>
10	<p>APC/14/18 – Date, Time and Venue of the next meeting</p> <p>The next meeting will be held on Wednesday 12th March 2014 at 1:30 – 3:30pm in the Gallery, Huyton Civic Suite, Civic Way Off Poplar Bank, Huyton. L36 9GD</p> <p>The Chair will be Peter Johnstone.</p>	

--	--	--

The agenda and minutes of this meeting may be made available to public and persons outside of The Pan Mersey Area Prescribing Committee Health Community in order to comply with requests made under the Freedom of Information Act 2000.